FDMT
$8.61-0.37 (-4.12%)
4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States.
Recent News
4D Molecular Therapeutics, Inc. (FDMT) Q4 Earnings and Revenues Beat Estimates
4D Molecular Therapeutics (FDMT) delivered earnings and revenue surprises of +180.75% and +147.86%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
4D Molecular Therapeutics Highlights 4D-150 Phase III Momentum, DME Plans, Cash Runway at Leerink Conference
Executives from 4D Molecular Therapeutics (NASDAQ:FDMT) provided updates on the company’s late-stage ophthalmology program, commercialization planning, cystic fibrosis development efforts, and cash runway during an appearance at the 2026 Leerink Partners Global Healthcare Conference in Miami. Phase
4D Molecular Therapeutics Maps Phase 3 4D-150 Timeline, DME Expansion in Barclays Conference Talk
Executives from 4D Molecular Therapeutics (NASDAQ:FDMT) outlined the company’s gene therapy platform, clinical progress, and commercialization plans during a Barclays analyst discussion in Miami, highlighting its lead retinal program 4D-150 and an earlier-stage effort in cystic fibrosis. Company ov
Where is 4D Molecular Therapeutics (FDMT) Headed According to the Street?
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) is one of the top gene therapy stocks to buy according to hedge funds. 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) announced enrollment completion for 4FRONT-1, the first Phase 3 clinical trial evaluating 4D-150 in patients with wet age-related macular degeneration (wet AMD), on February 9. 4FRONT-1 is a Phase 3 multicenter, […]
Barclays Flags M&A Tailwinds and Pricing Relief as Upside Catalysts for 4D Molecular Therapeutics, Inc. (FDMT)
We recently compiled a list of the 20 Best Biotech Stocks Under $20 to Buy Now. The fifteenth stock that takes place on our list is 4D Molecular Therapeutics, Inc. TheFly reported on January 27 that Barclays initiated coverage of FDMT with an Overweight rating and a $33 price target. Positive considerations for FDMT and […]